New York, June 5, 2026, 04:17 EDT
- Pyxis Oncology last traded at $1.71, up roughly 1.8% from its previous close. The company’s market cap is around $109 million.
- Jefferies hosted management on June 4, shifting focus again to the expected mid-year MICVO readout in head and neck cancer.
- Funding is still the main risk. Pyxis says it has enough cash to last only into the fourth quarter of 2026.
Shares of Pyxis Oncology ticked higher early Friday as management spoke at the Jefferies Global Healthcare Conference in New York. The company is set to release clinical data from its main program. Pyxis last traded at $1.71, up 3 cents from Thursday’s close, market data showed.
Timing is in focus. Pyxis is moving toward a mid-year data update for micvotabart pelidotin (MICVO) in second-line or later recurrent or metastatic head and neck squamous cell carcinoma. That means cancer that’s come back or spread after earlier treatment. On its investor site, the company put up a Jefferies fireside chat for June 4 at 7:35 a.m. EDT — a slot that puts management in front of healthcare investors a few weeks before the expected data.
Nasdaq’s main session was still closed in New York. Premarket runs 4:00 a.m. to 9:30 a.m. Eastern, with normal trading set for 9:30 a.m. to 4:00 p.m. Nasdaq’s 2026 holiday list does not include June 5.
Pyxis’ main drug is an antibody-drug conjugate, or ADC. This kind of drug ties an antibody to a cancer-killing agent, aiming to bring the treatment straight to tumor cells. The National Cancer Institute calls ADCs drugs that connect to certain cells and push the attached medication inside.
Pyxis said back in May it was still on schedule to report new MICVO monotherapy data for second-line-plus recurrent or metastatic head and neck cancer by mid-year 2026, with combination data with pembrolizumab expected in the second half of the year. The company also finished target enrollment for its Phase 1 monotherapy dose-expansion trial in the first quarter.
Pyxis Oncology’s interim CEO Tom Civik said the company is “on track to share updated monotherapy data in mid-year 2026,” according to results out May 14. The release showed first-quarter net loss at $23.3 million, or 37 cents a share, widening from $21.2 million, or 35 cents a share, a year before. Pyxis Oncology
Cash matters too. Pyxis had $42.5 million in cash, restricted cash and short-term investments as of March 31. The company says that will cover operations into the fourth quarter of 2026. That leaves a clinical runway, but the window is not long.
Civik said in March that reaching full enrollment for the MICVO monotherapy study was “an important milestone.” At the same time, Pyxis noted that MICVO was being studied both as a single agent and with Merck’s Keytruda. The company also pointed out that the program had FDA Fast Track status for certain adults with recurrent or metastatic head and neck cancer who already went through platinum chemotherapy and anti-PD-(L)1 therapy. GlobeNewswire
ADC Therapeutics shares fell Thursday after the company said more patients died in a late-stage blood cancer study, Reuters reported. The trial still hit its main endpoint, but deaths rose. Guggenheim’s Michael Schmidt said some other results looked good, but safety took the focus—the death rate weighed on the news. The sector stays tough.
MacroGenics has its own antibody oncology pipeline, with ADCs like MGC026 and MGC028 aimed at solid tumors. For Pyxis investors, the focus isn’t about matching every indication, but about proving the same thing: can early results stay strong, and is safety good enough to take these drugs into bigger trials?
Pyxis spelled out the risk in its quarterly filing. The company said its cash and marketable debt won’t cover operations for 12 months starting from the filing date, so there’s significant doubt about staying a going concern. Pyxis still has $150 million left to raise through an at-the-market share sale, according to the filing. That could give it more funding, but it could also dilute current holders if Pyxis taps it.
Right now, the stock isn’t moving on revenue. It’s the next data packet that matters. That’s common in small-cap biotech, and it’s a fragile setup. If the MICVO update comes in strong, it could push out the financing runway debate. But if the update disappoints, that conversation probably gets pulled forward.
